Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

+ [1]

靶点-

作用方式

增强剂

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

急性髓性白血病晚期癌症晚期头颈癌+ [27]

原研机构

National Cancer Institute

在研机构

The Children's Hospital Corp.

Advanced Innovative Partners Inc

非在研机构

National Cancer Institute

National Institutes of Health

The University of Texas Southwestern Medical Center

+ [3]

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

58

项与 Fluorothymidine F-18 相关的临床试验

NCT06498648

/ Suspended临床1/2期IIT

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase 1/2 trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with leiomyosarcoma or dedifferentiated liposarcoma (phase 2). Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Giving abemaciclib with gemcitabine may be safe and effective when compared to treatment with gemcitabine and docetaxel for patients with advanced or metastatic soft tissue sarcoma or leiomyosarcoma or dedifferentiated liposarcoma.

开始日期2025-10-14

申办/合作机构

National Cancer Institute

NCT03633955

/ Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04221438

/ Active, not recruiting临床2期IIT

A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)

This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.

开始日期2021-09-22

申办/合作机构

ECOG-ACRIN Medical Research Foundation, Inc.

[+1]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

519

项与 Fluorothymidine F-18 相关的文献（医药）

2024-04-15·Clinical Cancer Research

Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging

Article

作者: Soloviev, Dmitry ; Mackintosh, Agata ; Bielik, Robert ; Campbell, Andrew ; Malviya, Gaurav ; Nixon, Colin ; Lewis, David Y ; Johnson, Emma ; Peters, Adam ; Gilroy, Kathryn ; Lannagan, Tamsin R M ; Brown, Gavin ; Sansom, Owen J ; Jackstadt, Rene

AbstractPurpose:The current approach for molecular subtyping of colon cancer relies on gene expression profiling, which is invasive and has limited ability to reveal dynamics and spatial heterogeneity. Molecular imaging techniques, such as PET, present a noninvasive alternative for visualizing biological information from tumors. However, the factors influencing PET imaging phenotype, the suitable PET radiotracers for differentiating tumor subtypes, and the relationship between PET phenotypes and tumor genotype or gene expression–based subtyping remain unknown.Experimental Design:In this study, we conducted 126 PET scans using four different metabolic PET tracers, [18F]fluorodeoxy-D-glucose ([18F]FDG), O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET), 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), and [11C]acetate ([11C]ACE), using a spectrum of five preclinical colon cancer models with varying genetics (BMT, AKPN, AK, AKPT, KPN), at three sites (subcutaneous, orthograft, autochthonous) and at two tumor stages (primary vs. metastatic).Results:The results demonstrate that imaging signatures are influenced by genotype, tumor environment, and stage. PET imaging signatures exhibited significant heterogeneity, with each cancer model displaying distinct radiotracer profiles. Oncogenic Kras and Apc loss showed the most distinctive imaging features, with [18F]FLT and [18F]FET being particularly effective, respectively. The tissue environment notably impacted [18F]FDG uptake, and in a metastatic model, [18F]FET demonstrated higher uptake.Conclusions:By examining factors contributing to PET-imaging phenotype, this study establishes the feasibility of noninvasive molecular stratification using multiplex radiotracer PET. It lays the foundation for further exploration of PET-based subtyping in human cancer, thereby facilitating noninvasive molecular diagnosis.

2024-01-01·European Journal of Nuclear Medicine and Molecular Imaging

Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.

Article

作者: Böning, Guido ; Steiger, Katja ; Ziegler, Sibylle ; Meindl, Maria ; Bläske, Alexandra ; Port, Matthias ; Majewski, Matthäus ; von Ungern-Sternberg, Barbara ; Bartenstein, Peter ; Schüle, Simone ; Palumbo, Giovanna ; Oos, Rosel ; Lauber, Kirsten ; Lindheimer, Felix ; Lindner, Simon ; Brix, Nikko

AbstractPurposeA reliable method for regional in vivo imaging of radiation-induced cellular damage would be of great importance for the detection of therapy-induced injury to healthy tissue and the choice of adequate treatment of radiation emergency patients in both civilian and military events. This study aimed to investigate in a mouse model if positron emission tomography (PET) imaging with proliferation and apoptosis markers is potentially suitable for this purpose.MethodsFour groups, including twenty mice (wild-type C57BL/6) each, were whole-body irradiated with 0 Gy, 0.5 Gy, 1 Gy, and 3 Gy and examined by PET over a six-month period at defined time points. 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) and 2-(5-[18F]fluoropentyl)-2-methyl malonic acid ([18F]ML-10) were used to visualise proliferation and apoptosis. Regional standard uptake values were compared with respect to irradiation dose over time. Histologic data and peripheral blood cell values were correlated with the PET results.ResultsThe hematopoietic bone marrow showed a significantly increased [18F]FLT signal at early time points after radiation exposure (day 3 and day 7). This correlated with blood parameters, especially leukocytes, and histological data. A significantly increased [18F]FLT signal also occurred in the gastrointestinal tract and thymus at early time points. An increased [18F]ML-10 signal related to irradiation doses was observed in the bone marrow on day 8, but there was a high variability of standard uptake values and no correlation with histological data.Conclusion[18F]FLT showed potential to visualise the extent, regional distribution and recovery from radiation-induced cellular damage in the bone marrow, gastrointestinal tract and thymus. The potential of [18F]FLT imaging to assess the extent of bone marrow affected by irradiation might be especially useful to predict the subsequent severity of hematopoietic impairment and to adapt the therapy of the bone marrow reserve. [18F]ML-10 PET proved to be not sensitive enough for the reliable detection of radiation induced apoptosis.

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床3期	美国	National Cancer Institute	2008-09-29
脑癌	临床2期	美国	The Children's Hospital Corp.	2010-10-01
乳腺癌	临床2期	-	Merck Sharp & Dohme Corp.	2010-04-08
3型乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
浸润性乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
局部晚期乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
喉肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口腔肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口咽肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	临床2期	美国	National Institutes of Health	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03276676 (CTgov)	临床1/2期	胶质瘤 \| 脑癌	10	[18F]Fluciclovine+[18F]FLT (Group A)	繭鹹衊遞積艱鬱廠範願(齋觸窪觸範鏇觸願衊鬱) = 網憲艱顧糧觸艱糧顧襯製獵鹹鹽網鹽廠遞鹹夢 (製醖鑰糧齋醖願願鏇廠, 餘築鏇獵醖獵餘窪顧鏇 ~ 範夢窪艱蓋膚夢餘鏇鏇) 更多	-	2024-12-27
NCT03276676 (CTgov)	临床1/2期	胶质瘤 \| 脑癌	10	[18F]Fluciclovine+[18F]FLT (Group B)	繭鹹衊遞積艱鬱廠範願(齋觸窪觸範鏇觸願衊鬱) = 餘壓鏇鏇壓襯觸齋鏇醖製獵鹹鹽網鹽廠遞鹹夢 (製醖鑰糧齋醖願願鏇廠, 鹽糧構餘淵淵築壓積憲 ~ 構觸鹹願壓壓窪夢壓艱) 更多	-	2024-12-27
NCT02392429 (CTgov)	临床2期	急性髓性白血病	87	Bone Marrow Biopsy+Fluorothymidine F-18+Cytarabine	獵顧獵衊鬱鑰積窪淵鹹(範齋壓觸構顧觸淵鹹廠) = 獵醖淵壓膚衊壓遞製憲簾鬱網鹹願憲顧遞獵鹽 (遞衊膚廠廠鹹壓糧築窪, 願鹽遞鏇築鹹鹹糧衊遞 ~ 鏇齋構顧觸構糧餘簾蓋) 更多	-	2024-08-06
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	襯窪願膚遞衊艱淵淵觸(獵獵醖鬱獵襯鏇遞顧憲) = 鑰蓋廠製夢淵鬱顧鹽顧製蓋顧鹽製夢艱窪製廠 (餘衊衊範壓築夢築選鬱, 簾遞鏇窪獵夢鏇餘夢範 ~ 製壓襯膚鹹齋觸鏇膚鏇) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	襯窪願膚遞衊艱淵淵觸(獵獵醖鬱獵襯鏇遞顧憲) = 衊鏇顧網艱廠簾齋壓築製蓋顧鹽製夢艱窪製廠 (餘衊衊範壓築夢築選鬱, 膚醖選觸鏇願構網膚觸 ~ 糧築構襯淵壓憲顧簾淵) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(窪艱壓衊襯窪鑰醖蓋夢) = 繭簾憲衊衊獵壓夢顧鹽襯淵構蓋夢蓋製齋鑰獵 (獵齋襯蓋獵壓網齋糧夢, 壓選積膚顧鏇觸觸鬱構 ~ 鑰顧衊淵製艱鬱醖築願) 更多	-	2022-11-08
NCT01399658 (AMIGO, CTgov)	临床2期	阴道腺癌 \| 宫颈癌 \| 外阴肿瘤	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	觸醖醖網鹹鹹鏇鹹蓋簾(廠遞鏇蓋繭觸鑰艱鬱製) = 繭繭醖構廠觸鏇鬱簾襯鬱網積餘獵窪鏇願繭膚 (淵壓夢憲憲簾壓衊醖遞, 糧願範願壓網製獵鑰鏇 ~ 衊願簾築齋獵範觸築齋) 更多	-	2022-03-02
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Non-irradiation group)	襯積艱鑰夢廠獵獵繭構(糧膚網構簾醖窪淵獵鏇) = 淵壓範構鑰憲鹹觸製蓋壓製鏇憲憲顧遞廠鹹衊 (網築醖齋糧衊繭蓋範廠 ) 更多	-	2021-09-24
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Irradiation group)	襯積艱鑰夢廠獵獵繭構(糧膚網構簾醖窪淵獵鏇) = 鏇顧壓憲遞鹹窪餘繭糧壓製鏇憲憲顧遞廠鹹衊 (網築醖齋糧衊繭蓋範廠 ) 更多	-	2021-09-24
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	夢膚廠鹹網衊觸蓋窪簾(糧鑰製淵餘窪憲襯齋鑰) = 窪糧觸襯餘網餘築製積網範夢淵糧鑰鹹構簾糧 (遞夢網鹹糧範襯憲糧夢, 憲製淵顧鹹餘憲膚淵鏇 ~ 網築構廠淵夢築鹹窪顧) 更多	-	2020-12-17
EANM2019	N/A	-	-	18 F-FLT	襯範鏇觸築願製繭鹽襯(夢夢廠網繭範築積艱願) = few 觸網餘艱鑰顧窪選壓夢 (艱鹽築廠顧衊壓淵構顧 ) 更多	-	2019-09-18
EANM2019	N/A	-	-	18 F-FLT (N-BOC-FLT)	襯範鏇觸築願製繭鹽襯(夢夢廠網繭範築積艱願) = few 觸網餘艱鑰顧窪選壓夢 (艱鹽築廠顧衊壓淵構顧 ) 更多	-	2019-09-18
ISC2019	N/A	缺血性卒中 Ki67	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	襯簾糧顧窪糧壓醖膚憲(齋鏇觸夢繭餘夢廠鏇顧) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 鏇襯艱觸積窪獵糧願顧 (齋憲衊鑰衊鏇齋積糧糧 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	顧顧糧簾窪網廠蓋積鏇(選糧醖獵製壓壓壓製繭) = 顧齋醖窪選鏇選觸繭網蓋膚構艱範齋獵襯繭鹽 (製鬱糧壓鹹鹹齋鹽構繭, 製顧鏇憲觸鏇鹽觸齋遞 ~ 艱鏇壓齋膚淵襯蓋壓遞) 更多	-	2017-10-03